Alamar Biosciences (ALMR) investor relations material

Market Opportunity and Platform Overview

• Precision proteomics platform launched in early 2024, achieving rapid adoption, especially in Alzheimer's research and among leading academic, clinical, and biopharma institutions worldwide.

• Proteomics market estimated at $50 billion, projected to reach $80 billion by 2035, with advanced proteomics as the fastest-growing segment.

• Platform uniquely combines ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range, and seamless automation.

• Proprietary NULISA technology delivers a 10,000-fold improvement in signal-to-noise ratio and attomolar sensitivity, protected by patents and trade secrets.

• Enables end-to-end proteomics workflows, from high-plex discovery to clinical diagnostics, supporting up to 1,000+ plex assays and addressing unmet needs in sensitivity and multiplexing.

Commercial Traction and Financial Performance

• Revenue grew from $25 million in the first year to $74 million in the second year, with Q1 2026 revenue nearly doubling year-over-year to $26 million and a 56% gross margin.

• Over 100 instruments installed, with industry-leading annual pull-through exceeding $400,000 per instrument.

• Consumables account for about 50% of total revenue; biopharma and CRO/clinical customers contributed 44% of revenue, including all top 10 pharma companies by 2024 revenue.

• Sales efficiency is high, with $3 million revenue per sales headcount, and a scalable team of 25 direct reps and 7 distributors as of early 2026.

• Demonstrated fastest adoption among advanced proteomics companies.

Scientific Impact and Product Development

• Over 124 publications in 8-9 quarters, spanning neurology, immunology, and oncology, with more than 40 focused on Alzheimer's disease.

• Major funding from Alzheimer's Drug Discovery Foundation ($10 million) to accelerate transition to FDA-cleared IVD platform, with submission expected next year.

• New product launches include Inflammation Panel (Jan 2024), CNS 120 marker panel (mid-2024), and NULISAseq Neuro 220 Panel (March 2024), with rapid adoption.

• Platform supports home brew assay kits and clinical biomarker panels, including brain-derived p-tau 217 and a 5-plex Alzheimer's assay.

• Collaborations with major neuro foundations and consortia, including Alzheimer's and Parkinson's research.